Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Cell Biochem ; 119(8): 6953-6960, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29737563

RESUMEN

Laryngeal squamous cell carcinoma (LSCC) is one aggressive malignancy and accounts for 20% of all head and neck cancer. However, the role of LOC554202 in human LSCC remains unknown. The expression level of LOC554202 and miR-31 was detected in the LSCC tiussues by using qRT-PCR. Cell growth was measured by CCK-8 assay. Flow cytometry and matrigel-coated membrane was used to detect for cell cycle and invasion respectively. We indicated that lncRNA LOC554202 expression was overexpressed in LSCC tissues compared with the paired adjacent samples and higher LOC554202 expression was associated with the advanced stage. In addition, we demonstrated that the expression level of miR-31 was downregulated in LSCC tissues compared to the paired adjacent samples and lower miR-31 expression was correlated with the advanced stage. Moreover, the expression of miR-31 was negatively correlated with the expression of LOC554202 in LSCC tissues. Ectopic expression of LOC554202 promoted LSCC cell growth, cell cyle and cell invasion and overexpression of miR-31 inhibited LSCC cell growth, cell cyle and cell invasion. Elevated expression of LOC554202 suppressed miR-31 expression and promoted RhoA expression in LSCC cell, which was a direct target gene of miR-31. Furthermore, LOC554202 increased LSCC cell growth, cell cyle and cell invasion through suppressing miR-31 expression. These results suggested that LOC554202 acted as an oncogene in the development of LSCC.


Asunto(s)
Carcinoma de Células Escamosas/metabolismo , Ciclo Celular , Regulación Neoplásica de la Expresión Génica , Neoplasias Laríngeas/metabolismo , MicroARNs/biosíntesis , ARN Largo no Codificante/biosíntesis , ARN Neoplásico/biosíntesis , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/patología , Humanos , Neoplasias Laríngeas/genética , Neoplasias Laríngeas/patología , MicroARNs/genética , Invasividad Neoplásica , Proteínas de Neoplasias/biosíntesis , Proteínas de Neoplasias/genética , ARN Largo no Codificante/genética , ARN Neoplásico/genética , Proteína de Unión al GTP rhoA/biosíntesis , Proteína de Unión al GTP rhoA/genética
2.
J Cell Biochem ; 119(7): 5118-5125, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29091303

RESUMEN

MicroRNAs (miRNAs) are aberrantly expressed in several tumors and play important role in tumorigenesis. However, little is known about the role of miR-613 in laryngeal squamous cell carcinoma (LSCC). We determined the expression of miR-613 in a panel of 30 LSCC specimens. Compared with the adjacent normal samples, 20 cases of LSCC tissues exhibited decreased expression of miR-613. The average expression of miR-613 in LSCC tissues was lower than in normal samples. Moreover, we demonstrated that exogenous expression of miR-613 suppressed LSCC cell proliferation, invasion, and blocked G1/S phase transition. We identified that 3-phosphoinositide-dependent protein kinase-1 (PDK1) was a direct target gene of miR-613 in LSCC cell. Overexpression of miR-613 suppressed PDK1 expression in LSCC cell. Furthermore, we demonstrated that PDK1 was upregulated in LSCC tissues. MiR-613 expression was inversely correlated with the expression of PDK1 in LSCC tissues. Moreover, we showed that PDK1 was involved in the miR-613-mediated cancer suppression of LSCC cell. These results suggested that miR-613 played as a tumor suppressor gene in LSCC partly by inhibiting PDK1 expression.


Asunto(s)
Neoplasias Laríngeas/genética , MicroARNs/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Western Blotting , Ciclo Celular/genética , Ciclo Celular/fisiología , Línea Celular Tumoral , Proliferación Celular/genética , Proliferación Celular/fisiología , Regulación Neoplásica de la Expresión Génica/genética , Humanos , MicroARNs/genética , Proteínas Serina-Treonina Quinasas/genética , Piruvato Deshidrogenasa Quinasa Acetil-Transferidora , Reacción en Cadena en Tiempo Real de la Polimerasa
3.
Mol Med Rep ; 17(1): 1269-1274, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-29115472

RESUMEN

Recent studies have demonstrated that resveratrol can reduce blood sugar, improve insulin resistance, regulate abnormalities in lipid metabolism, and lower the secretion and expression of inflammatory factors. The present study investigated the anti­inflammatory effects of resveratrol in animal models of acute pharyngitis, and its possible mechanisms. Commercial ELISA kits were used to measure tumor necrosis factor­α, interleukin (IL)­6, macrophage inflammatory protein­2, cyclooxygenase­2 levels and caspase­3/9 activity. Toll­like receptor (TLR)­4, myeloid differentiation primary response protein MyD88, phosphorylated (p)­nuclear factor (NF)­κB and p­IκB were analyzed using western blotting. In a rabbit model of acute pharyngitis, it was demonstrated that resveratrol inhibited tumor necrosis factor­α and interleukin­6 serum levels, macrophage inflammatory protein­2 and cyclooxygenase­2 activity levels, reactive oxygen species production and caspase­3/9 activity. Resveratrol suppressed NACHT, LRR and PYD domains­containing protein 3 and caspase­1 protein expression, and reduced IL­1ß and IL­18 protein expression in animal models of acute pharyngitis. Additionally, resveratrol suppressed TLR4 and myeloid differentiation primary response protein 88 protein expression, and reduced p­NF­κB and increased p­IκB protein expression in animal models of acute pharyngitis. In conclusion, these findings indicated that the anti­inflammatory activity of resveratrol prevents acute pharyngitis­induced inflammation by inhibiting NF­κB in animal models. Therefore, these data suggested an important clinical application of resveratrol in preventing acute pharyngitis.


Asunto(s)
Antiinflamatorios/farmacología , FN-kappa B/antagonistas & inhibidores , Faringitis/tratamiento farmacológico , Estilbenos/farmacología , Animales , Quimiocina CXCL2/metabolismo , Ciclooxigenasa 2/metabolismo , Evaluación Preclínica de Medicamentos , Interleucina-6/sangre , Masculino , Faringitis/metabolismo , Faringe/efectos de los fármacos , Faringe/inmunología , Faringe/metabolismo , Conejos , Especies Reactivas de Oxígeno/metabolismo , Resveratrol , Transducción de Señal , Factor de Necrosis Tumoral alfa/sangre
4.
Med Sci Monit ; 22: 4132-4138, 2016 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-27801393

RESUMEN

BACKGROUND The angiotensin-converting enzyme (ACE, CD143) gene plays a crucial role in the pathology of many cancers. Previous studies mostly focused on the gene polymorphism, but the other functions of ACE have rarely been reported. The purpose of this study was to investigate the expression of ACE and its biological function, as well as its prognostic value, in laryngeal cancer. MATERIAL AND METHODS The expression of ACE was detected by quantitative real-time polymerase chain reaction (qRT-PCR) analysis in 106 patients with laryngeal cancer and 85 healthy people. Then the cell proliferation was estimated after the cell lines Hep-2 were transfected with pGL3-ACE and empty vector, respectively. In addition, the relationship between ACE expression and clinicopathologic characteristics was analyzed. Finally, Kaplan-Meier analysis was used to evaluate the overall survival of patients with different ACE expression, while Cox regression analysis was conducted to reveal the prognostic value of ACE in laryngeal cancer. RESULTS Our results demonstrate that ACE is over-expressed in laryngeal cancer and thus promotes cell proliferation. The up-regulation of ACE was significantly influenced by tumor stage and lymph node metastasis. Patients with high ACE expression had a shorter overall survival compared with those with low ACE expression according to Kaplan-Meier analysis. The ACE gene was also found to be an important factor in the prognosis of laryngeal cancer. CONCLUSIONS Our study shows that the ACE gene was up-regulated, which promoted the cell proliferation, and it could be an independent prognostic marker in laryngeal cancer.


Asunto(s)
Neoplasias Laríngeas/enzimología , Peptidil-Dipeptidasa A/biosíntesis , Adulto , Anciano , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Carcinoma de Células Escamosas/enzimología , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/patología , Estudios de Casos y Controles , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Femenino , Neoplasias de Cabeza y Cuello/enzimología , Neoplasias de Cabeza y Cuello/genética , Neoplasias de Cabeza y Cuello/patología , Humanos , Inmunohistoquímica , Estimación de Kaplan-Meier , Neoplasias Laríngeas/genética , Neoplasias Laríngeas/patología , Masculino , Persona de Mediana Edad , Peptidil-Dipeptidasa A/genética , Pronóstico , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Carcinoma de Células Escamosas de Cabeza y Cuello , Regulación hacia Arriba
5.
Am J Transl Res ; 8(9): 3903-3911, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27725869

RESUMEN

Laryngeal squamous cell carcinoma (LSCC) is a common aggressive head and neck cancer with high mortality and incidence. MicroRNAs (miRNAs) are short, non-coding and endogenous RNAs that posttranscriptionally inhibit gene expression. In this study, we showed that miR-300 expression was downregulated in LSCC tissues compared with adjacent no-tumor tissues. MiR-300 overexpression inhibited Hep-2 cell proliferation, as well as the expression of ki-67 and PCNA. Moreover, overexpression of miR-300 repressed the cell invasion in Hep-2 cells. We identified c-ros oncogene 1 receptor tyrosine kinase (ROS1) as a direct target gene of miR-300 in Hep-2 cell. Furthermore, ROS1 expression was upregulated in LSCC tissues compared with adjacent no-tumor tissues. Interesting, there were an inverse correlation between ROS1 and miR-300 expression in the LSCC tissues. Overexpression of ROS1 increased the Hep-2 cells proliferation and invasion. Overexpression of ROS1 abrogated miR-300 induced cell growth and invasion inhibition. Therefore, our data suggested that miR-300 acted as a tumor suppressive gene in LSCC.

6.
Pharmazie ; 71(10): 598-602, 2016 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-29441929

RESUMEN

Cisplatin-based chemotherapy has been found to improve the prognosis of patients with tongue squamous cell carcinoma (TSCC), the most common oral cancer with a poor prognosis. Chemoresistance to cisplatin appears to be an important clinical problem for cisplatin-based TSCC chemotherapy. Long noncoding RNAs (lncRNAs) play important roles in regulating tumor cells' sensitivity to chemotherapeutic agents. A recent study has shown that the expression of lncRNA UCA1 is significantly enhanced in TSCCs, suggesting that UCA1 may play a role in TSCC progression. In the present study, we explored the effects and the underlying mechanisms of UCA1 on cisplatin chemosensitivity/chemoresistance and apoptosis in TSCC cells. Transient transfection of siRNA was used to knock down UCA1 in human TSCC cell lines CAL 27 and SCC-9, where UCA1 was highly overexpressed compared to normal human tongue tissues. Knockdown of UCA1 markedly increased cisplatin-induced caspase 3 activity and apoptosis in CAL 27 and SCC-9 cells. On the other hand, it decreased cisplatin-induced phosphatidylinositol 3-kinase (PI3K) activity and activation phosphorylation of Akt. UCA1 knockdown resulted in one magnitude decrease in the half maximal inhibitory concentration (IC50) of cisplatin in CAL 27 and SCC-9 cells, from 8.9 mM and 20.7 mM down to 0.6 mM and 1.7 mM, respectively. In conclusion, this study has shown that UCA1 knockdown markedly increased cisplatin-induced apoptosis and chemosensitivity in TSCC cells, likely through inhibiting cisplatin-activated PI3K/Akt signaling. It provides new insights into the functional role of UCA1 in cancer cells and suggests that UCA1 knockdown could be a new strategy to increase cisplatin chemosensitivity and thereby improve the therapeutic outcomes of cisplatin-based chemotherapy for TSCC.


Asunto(s)
Antineoplásicos/farmacología , Carcinoma de Células Escamosas/tratamiento farmacológico , Cisplatino/farmacología , ARN Largo no Codificante/genética , Neoplasias de la Lengua/tratamiento farmacológico , Apoptosis/efectos de los fármacos , Caspasa 3/biosíntesis , Caspasa 3/genética , Línea Celular Tumoral , Resistencia a Antineoplásicos/genética , Técnicas de Silenciamiento del Gen , Humanos , Proteína Oncogénica v-akt/biosíntesis , Proteína Oncogénica v-akt/genética , Fosfatidilinositol 3-Quinasas , ARN Interferente Pequeño/farmacología , Transducción de Señal/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...